Treatment Outcomes in COVID-19 patients with comorbidities in Kaduna state, Northwestern Nigeria
DOI:
https://doi.org/10.60787/tnhj.v23i1.653Keywords:
COVID 19, Comorbidities, Outcome, Retrospective, Diabetes careAbstract
Background: Severe COVID-19 disease has been reported among people with underlying conditions such as diabetes, chronic respiratory diseases, cancer, obesity, and cardiovascular disease. This study determined the outcomes of COVID-19 among patients with comorbidities in Kaduna state, where we have the highest incidence in northern Nigeria.
Methods: This study was a retrospective, descriptive cross-sectional review of the clinical records involving all age groups of 902 COVID-19 patients admitted at the four isolation centers of the Kaduna State Infectious Disease Control Centre (IDCC) between March 27th 2020 to December 31st 2021. Data was analyzed with SPSS version 25 and STATA SE 12 with p <0.05.
Results: Out of the 902 cases, 245 (27.2%) had comorbidities, hypertension 206(22.8%) was the most recorded comorbidity, others were diabetes 77(8.5%), asthma 7 (0.78%), HIV 7(0.78%), sickle cell anemia 7 (0.78%) and PTB 3 (0.33%). Patients with comorbidities had prolonged mean duration of symptoms 8.36±3.5 days, compared to 7.2±2.7 days in those without comorbidities (p=0.001). Multivariate logistic regression analysis further shows that the odds for clinical recovery from the COVID-19 disease was significantly lower for patient with hypertension (AOR=0.13, 95%CI=0.06-0.27, p = <0.01), diabetic (AOR=0.20, 95% CI=0.10-0.40, p<0.01) and HIV comorbidities (AOR=0.1, 95%CI=0.01-0.98, p=0.05) compared to those without comorbidities
Conclusion: Hypertension and diabetes were the major comorbidities in this study. Most patients with comorbidities had severe presentations and fatal poorer outcome. There is a need for sustained public health education targeted at patients with chronic diseases to be screened and treated early for COVID 19 Disease.
Downloads
References
Bamidele JO, Daniel OJ. Epidemiology of coronavirus disease (COVID-19) in Nigeria. Annals of Health Research. 2020 May 17;6(2):125 DOI:https://doi.org/10.30442/ahr.0602-01-74
Aberhe W, Mariye T, Hailay A, Zereabruk K, Mebrahtom G, Gebremedhn G, Haile T, Guesh T. The burden and outcomes of COVID-19 among patients with co-morbid disease in Africa: protocol for a systematic review and meta-analysis. New Microbes and New Infections. 2021 Jan 1;39:100802. https://doi.org/10.1016/j.nmni.2020.1008021
Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. The Tohoku journal of experimental medicine. 2020;250(4):271-8. https://doi.org/10.1016/j.nmni.2020.1008021
Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Archives of Iranian medicine. 2020 Apr 1;23(4):268.https://doi.org/10.34172/aim.2020.09
Sohrabi C, Alsafi Z, O'neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International journal of surgery. 2020 Apr 1;76:71-6.https://doi.org/10.1016/j.ijsu.2020.02.034
Shahreen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristic of human coronaviruses. J Adv Res. 2020;24(7):91-8. https://doi.org/10.1016/j.jare.2020.03.005
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The lancet. 2020 Feb 15;395(10223):473-5.https://doi.org/10.1016/j.jaut.2020.102433
Harper CA, Satchell LP, Fido D, Latzman RD. Functional fear predicts public health compliance in the COVID-19 pandemic. International journal of mental health and addiction. 2021 Oct; 19:1875-88. https://doi.org/10.15446/revfacmed.v68n1.86482
Beurnier A, Jutant EM, Jevnikar M, Boucly A, Pichon J, Preda M, Frank M, Laurent J, Richard C, Monnet X, Duranteau J. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. European Respiratory Journal. 2020 Nov 1;56(5). https://doi.org/10.1183/13993003.01875-2020
Alshukry A, Abbas MB, Ali Y, Alahmad B, Al-Shammari AA, Alhamar G, Abu-Farha M, AbuBaker J, Devarajan S, Dashti AA, Al-Mulla F. Clinical characteristics and outcomes of COVID-19 patients with diabetes mellitus in Kuwait. Heliyon. 2021 Apr 1;7(4):e06706. https://doi.org/10.1016/j.heliyon.2021.e06706
Alshukry A, Abbas MB, Ali Y, Alahmad B, Al-Shammari AA, Abu-farha M, Abubakr J, Devarajan S, Dashti AA, Al-Mulla F, Ali H. Clinical characteristics and outcomes of diabetic cOVID-19 patients in Kuwait. medRxiv. 2020;15(11):1-6.
Li X, Xu S, Yu M. Wang, k. Liu, L., Xin, J., Yang, H. and Gao. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020:2085-91. https://doi.org/10.1016/j.jaci.2020.04.006
Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, Italia L, Zaccone G, Tedino C, Fabbricatore D, Curnis A. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European heart journal. 2020 May 14;41(19):1821-9. https://doi.org/10.1016/j.jaci.2020.04.006
Almalki ZS, Khan MF, Almazrou S, Alanazi AS, Iqbal MS, Alqahtani A, Alghamdi S, Alahmari AK. Clinical characteristics and outcomes among COVID-19 hospitalized patients with chronic conditions: A retrospective single-center study. Journal of Multidisciplinary Healthcare. 2020 Oct 6:1089-97. https://doi.org/10.2147/JMDH.S273918
Albadawy RM, Jadoon BA, Mogahed MM, Ibrahim ME, Essawy TS, Amin AM, Abd-Elraouf MS, Elawady MA. The impact of comorbidities on the outcomes of Egyptian COVID-19 patients: a follow-up study. Journal of Environmental and Public Health. 2021 Jun 17;2021:1-7. https://doi.org/10.1155/2021/6662476
Akande OW, Akande TM. COVID-19 pandemic: A global health burden. Nigerian Postgraduate Medical Journal. 2020 Jul 1;27(3):147. https://doi.org/10.4103/npmj.npmj_157_20
Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, Wright O, Adeseun R, Mutiu B, Saka B, Osa N. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PloS one. 2021 Mar 15;16(3):e0248281.
Oyefabi A, Musa S, Kambai H, Usman I, Gwamna J, Sheyin J, Ige O, Abdullahi M, Sunday J, Kera HN, Atiku A. Comparison of the Ivermectin and Lopinavir/Ritonavir Treatment Outcomes among COVID-19 Mild to Moderate Cases in Kaduna State. West African Journal of Medicine. 2022 Feb 1;39(2):140-6.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020 May 26;323(20):2052-9. https://doi.org/10.1001/jama.2020.6775
Mohan A, Tiwari P, Bhatnagar S, Patel A, Maurya A, Dar L, Pahuja S, Garg R, Gupta N, Sahoo B, Gupta R. Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India. The Indian journal of medical research. 2020 Jul;152(1-2):61. https://doi.org/10.4103/ijmr.IJMR_1788_20
NCDC. COVID-19 Situation Report: Situation Report 95. Niger Cent Dis Control [Internet].2021;95(June):1–4. Available from: https://ncdc.gov.ng/themes/common/files/sitreps/fe61a5d7bba46e835a7f6d09bd5343c8.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal and Publisher
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
